Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEH5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $45,414
Award facts
- Contract value 100% obligated
- $45,413.92 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $45,413.92 to DMS Pharmaceutical Group Inc. for Xolair 300 mg/2 mL auto-injector syringes on January 28, 2026. This firm fixed-price delivery order, which will be completed by February 19, 2026, was awarded without set-aside designation, demonstrating the vendor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group Inc. is a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, specializing in distributing pharmaceutical products and medical consumables to federal agencies, particularly the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that positions the company as one of multiple regional prime vendor contractors. The parent contract, valued at $499 million with a completion date of December 31, 2036, authorizes the DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare operations globally. The delivery order for Xolair, an immunosuppressant biologic agent, represents part of DMS Pharmaceutical Group's critical role in supplying specialized pharmaceutical products to military healthcare facilities worldwide.
Quick answers
Who was awarded contract SPE2DR26FMEH5?
SPE2DR26FMEH5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 28, 2026.
How much is contract SPE2DR26FMEH5 worth?
The government has obligated $45,414 on SPE2DR26FMEH5.
Is contract SPE2DR26FMEH5 an order under another contract?
Yes. SPE2DR26FMEH5 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEH5 competed?
The extent of competition for SPE2DR26FMEH5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award